Jamia Hamdard, Faculty of Pharmacy, Department of Pharmaceutics, Delhi, India.
Saudi Pharm J. 2013 Jul;21(3):293-304. doi: 10.1016/j.jsps.2013.03.005. Epub 2013 Apr 17.
The present work deals with various attempts to prepare a gastroretentive formulation of lacidipine for treating gastroparesis. High density sucrose beads were modified by coating with certain polymers, but unfortunately sustained release could not be achieved. Granules were prepared by wet granulation technology using different combinations of polymers and a release of the drug was observed. The method failed to release the drug as per desired specifications. Polymeric coating followed by wet granulation was thought to be a better process to sustain the dissolution rate. The release rate can be modified by the incorporation of different polymeric coatings, but the mucoadhesive potential of granules was only 4.23% which might be due to its large size and the presence of other ingredients. Further, the lacidipine loaded microparticles were prepared by different methods such as compression, ionic gelation with TPP, ionic gelation with TPP and glutaraldehyde, spray drying and coacervation techniques. The formulations were evaluated for average particle size, surface morphology, entrapment efficiency, % yield and mucoadhesive potential. The microparticles prepared by compression method using HPMC K4M and SCMC as mucoadhesive polymers and BaSO4 as high density diluent showed poor bioadhesion (8.3%) and poor release characteristics (100% in 120 min). Ionic gelation with tripolyphosphate yielded microspheres with poor mechanical strength. In order to improve its mechanical strength, TPP ionic gelation was combined with step-wise cross-linking with glutaraldehyde. The additional solidification step to improve mechanical strength left this procedure tedious, time consuming and cytotoxic. Spray drying method gave a very low yield with 46.67% bioadhesion. The method using CaCl2 for ionotropic gelation showed the best results with regard to physical characteristics (well formed discrete, spherical surface microcapsule), particle size (88.57 ± 0.51), in vitro bioadhesion (67.33%), yield (>85%) and loading (>70%).
本工作涉及到各种尝试制备拉西地平的胃滞留制剂来治疗胃轻瘫。高密度蔗糖珠通过用某些聚合物涂覆来进行改性,但不幸的是不能实现持续释放。通过使用不同的聚合物组合的湿法制粒技术制备颗粒,并观察到药物的释放。该方法未能按照所需规格释放药物。认为聚合物包衣后进行湿法制粒是维持溶解速率的更好方法。可以通过加入不同的聚合物涂层来修改释放速率,但颗粒的粘膜粘附潜力仅为 4.23%,这可能是由于其尺寸较大以及存在其他成分。此外,通过不同的方法制备了载拉西地平的微球,例如压缩、与 TPP 的离子凝胶化、与 TPP 和戊二醛的离子凝胶化、喷雾干燥和凝聚技术。对制剂进行平均粒径、表面形态、包封效率、%产率和粘膜粘附潜力的评价。使用 HPMC K4M 和 SCMC 作为粘膜粘附聚合物以及 BaSO4 作为高密度稀释剂通过压缩法制备的微球表现出较差的生物粘附性(8.3%)和较差的释放特性(120 分钟内 100%)。与三磷酸五钠的离子凝胶化产生机械强度差的微球。为了提高其机械强度,将 TPP 离子凝胶化与戊二醛的逐步交联相结合。增加的固化步骤以提高机械强度使该过程繁琐、耗时且细胞毒性。喷雾干燥法的产率非常低,只有 46.67%的生物粘附性。使用 CaCl2 进行离子凝胶化的方法在物理特性(形成良好的离散、球形表面微胶囊)、粒径(88.57 ± 0.51)、体外生物粘附性(67.33%)、产率(>85%)和载药量(>70%)方面显示出最佳结果。